共 243 条
[11]
Laakso M(2013)Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 372-382
[12]
Low Wang CC(2013)Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 56 2582-2592
[13]
Hess CN(2013)Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 67 1267-1282
[14]
Hiatt WR(2014)Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Diabetes Obes Metab 16 467-477
[15]
Goldfine AB(2015)Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus J Diabetes Complications 29 438-444
[16]
Inzucchi SE(2007)Prevalence of self-reported cardiovascular disease among persons aged ≥35 years with diabetes—United States, 1997–2005 MMWR Wkly 56 1129-1132
[17]
Zinman B(2009)Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study J Am Acad Nurse Pract 21 140-148
[18]
Wanner C(2014)Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results Postgrad Med 126 16-34
[19]
Ferrari R(2015)Canagliflozin for the treatment of adults with type 2 diabetes Diabetes Manag 5 183-201
[20]
Fitchett D(2015)Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials Curr Med Res Opin 31 1993-2000